Ron van Schaik
13:30-14:45 - session: Combining data keeps you fit!
Prof. Dr. Ron van Schaik (PhD, FACB) is a registered European Specialist Laboratory Medicine and a Full Professor of Pharmacogenetics. He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, and is Director of the International (IFCC) Expertcenter for Pharmacogenetics. Main interest is the implementation of pharmacogenetics in clinical practice, and associated with this, pharmacogenetic translational research. In 2013, he introduced the “DNA passport for Medication”: s summary of genetic results aimed at drug metabolizing capacity for each patient.
Specific research topics are DNA analyses with respect to drug treatment in oncology, cardiology, pain, solid organ transplantation and psychiatry. He has published over 300 articles on pharmacogenetics. Prof van Schaik participates in several National and International advisory committees on Pharmacogenetics (a.o. chair of the European Clinical Pharmacogenetics Implementation Consortium (Eu-PIC; chair (www.eu-pic.eu), President of the European Society for Pharmacogenomics and Personalized Therapy (www.esptsociety.eu) and advisor of the Pharmacogenetics Working Group of the European Medicine Agency (EMA). In 2001, he received the Ortho Clinical Diagnostics Award for Outstanding Research, in 2009 the AACC Outstanding Speaker Award, and in 2010 the AACC/Mol Pathology Award for Outstanding Scientific Research.
Pharmacogenetics: Do you have your DNA-passport?
Adverse drug reactions (ADRs) are a major problem in treating patients: they are responsible for 5-7% of hospitalizations. Inter individual variation in drug metabolism is part of this problem. DNA analysis can predict the drugs metabolizing capacity of each individual. Cytochrome P450 (CYP) enzymes are involved in the metabolism of 80% of all drugs. For example, CYP2D6 is involved in the metabolism of many drugs, covering psychiatry, oncology, cardiology and pain medication. Yet, 5-10% of the population is CYP2D6 deficient due to inheritance of two defective alleles, causing either side effects on standard therapy (e.g. psychiatric drugs) or ineffective treatment (tramadol, codeine). Such a deficiency can be tested for by a simple blood or cheek swab analysis, and drug therapy can be adjusted upfront: personalized medicine.
How far are we with implementing Pharmacogenetics in clinical practice in Europe? In the Netherlands, any person can go with his/her DNA passport to any pharmacy to obtain medication dosage adjusted on their genomic profile for over 90 drugs, based on genotype results of 13 drug metabolizing enzyme genes. Yet, the number of actionable genes is rapidly expanding (30-100), as is the number of drugs involved (300 – 3000). Several reporting platforms now also include, next to gene-drug interactions, the drug-drug interactions and even life style information. The challenge is how this huge amount of information can be made accessible for day to day health care.
Health-RI Conference 2020Registration website for Health-RI Conference 2020
Health-RI Conference firstname.lastname@example.org
Health-RI Conference email@example.com://www.aanmelder.nl/hri2020
Health-RI Conference 2020Health-RI Conference 20200.00EUROnlineOnly2019-01-01T00:00:00ZTo be announcedTo be announced